Literature DB >> 28834471

Evolocumab in Patients with Cardiovascular Disease.

Marc S Sabatine1,2, Robert P Giugliano1, Terje R Pedersen3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28834471     DOI： 10.1056/NEJMc1708587

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

Review 1.  Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?

Authors:  Stefan Weisshaar; Markus Zeitlinger
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

Review 2.  [Antibodies as treatment option in older adults].

Authors:  M Gosch; S Wicklein
Journal:  Z Gerontol Geriatr       Date:  2017-12-20       Impact factor: 1.281

3.  Clinical Management of High and Very High Risk Patients with Hyperlipidaemia in Central and Eastern Europe: An Observational Study.

Authors:  Ivo Petrov; Andreea Dumitrescu; Michaela Snejdrlova; Barak Zafrir; Beata Wożakowska-Kapłon; Lubomira Fabryova; Hrvoje Pintarić; Ian Bridges; Reneta Petkova
Journal:  Adv Ther       Date:  2019-02-13       Impact factor: 3.845

4.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer's disease: A genetic and proteomic multi-cohort study.

Authors:  Cynthia Picard; Alexandre Poirier; Stéphanie Bélanger; Anne Labonté; Daniel Auld; Judes Poirier
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

5.  Applicability of the REDUCE-IT trial to the FAST-MI registry. Are the results of randomized trials relevant in routine clinical practice?

Authors:  Jean Ferrières; Vincent Bataille; Etienne Puymirat; François Schiele; Tabassome Simon; Nicolas Danchin
Journal:  Clin Cardiol       Date:  2020-07-28       Impact factor: 2.882

Review 6.  Plasma Ceramides in Cardiovascular Disease Risk Stratification.

Authors:  Débora L M Junqueira; Alline Stach; Adriano Caixeta; Juliana Sallum; Erika Yasaki; Jeane Tsutsui; Edgar Rizatti; Carlos E Rochitte; Jean-Paul Kovalik; José E Krieger; A Mark Richards; Mark Y Chan; Leonardo P de Carvalho
Journal:  Arq Bras Cardiol       Date:  2022-04       Impact factor: 2.000

7.  Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease.

Authors:  Iryna Dykun; Daniela Wiefhoff; Matthias Totzeck; Fadi Al-Rashid; R Alexander Jánosi; Tienush Rassaf; Amir A Mahabadi
Journal:  Int J Cardiol Heart Vasc       Date:  2018-12-28

8.  Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability.

Authors:  Hans Ericsson; Karin Nelander; Maria Heijer; Magnus Kjaer; Eva-Lotte Lindstedt; Muna Albayaty; Pablo Forte; Maria Lagerström-Fermér; Stanko Skrtic
Journal:  Clin Pharmacol Drug Dev       Date:  2019-12-02

9.  Familial Hypercholesterolaemia in a Bulgarian Population of Patients with Dyslipidaemia and Diabetes: An Observational Study.

Authors:  Tsvetalina Tankova; Atanaska Elenkova; Ralitsa Robeva; Roumyana Dimova; Anna-Maria Borissova; Adrian Olszewski; Vasil Lachev; Reneta Petkova
Journal:  Diabetes Ther       Date:  2020-01-02       Impact factor: 2.945
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.